iShares 7-10 Year Treasury Bond ETF vs Johnson & Johnson — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.09, while Johnson & Johnson trades at $260.19 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | JNJ | |
|---|---|---|
52-Week High | $97.99 | $267.24 |
52-Week Low | $92.76 | $172.78 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Sector | — | Health |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Signals from Pluang's Aura AI — not financial advice
IEF, an ETF tracking 7-10 year US Treasury bonds, trades at $93.13, up 0.4% on the day. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators are neutral. Recent news highlights institutional buying interest amid rising Treasury yields and inflation concerns. The ETF pays regular dividends, with recent distributions around $0.31-$0.32 per share.
The outlook for IEF hinges on interest rate trends and inflation data. Higher yields may pressure prices, but institutional accumulation suggests long-term confidence. Key risks include Fed policy shifts and geopolitical tensions affecting oil prices and bond markets. Investors should weigh yield attractiveness against duration risk in a volatile rate environment.
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Trailing returns across standard periods
Latest headlines on both assets
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →